Ricevi le ultime notizie sulle azioni Molecular Partners con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MOLN

Ultime notizie per

Molecular Partners

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG - American Depositary Shares

Molecular Partners AG

News

Press Releases

Molecular Partners to hold three poster presentations at AACR 2025

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Health Care

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Earnings

Molecular Partners Reports Financial Results and Highlights from Q1 2025

Molecular Partners to Present at Upcoming Investor Conferences

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

General

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

Management

Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

MOLN

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Alpha Cognition

Agenus

Alector

Anika Therapeutics

Anixa Biosciences

Climb Bio

Cardiff Oncology

Citius Oncology

Elicio Therapeutics

Forte Biosciences

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Opus Genetics

MDxHealth

Nuvectis Pharma

Oncolytics Biotech

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Spero Therapeutics

TScan Therapeutics

Instil Bio

Tevogen Bio Holdings

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

JP Morgan

LifeSci Capital

Comments

Molecular Partners Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO